Asset Details
Do you wish to reserve the book?
Clinical relevance of circulating MACC1 and S100A4 transcripts for ovarian cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical relevance of circulating MACC1 and S100A4 transcripts for ovarian cancer
Do you wish to request the book?
Clinical relevance of circulating MACC1 and S100A4 transcripts for ovarian cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical relevance of circulating MACC1 and S100A4 transcripts for ovarian cancer
2019
Overview
Metastasis‐associated in colon cancer 1 (MACC1) and S100 calcium‐binding protein A4 (S100A4) are prominent inducers of tumor progression and metastasis. For the first time, we systematically tracked circulating serum levels of MACC1 and S100A4 transcripts in the course of surgery and chemotherapy and analyzed their clinical relevance for ovarian cancer. MACC1 and S100A4 transcripts were quantified in a total of 318 serum samples from 79 ovarian cancer patients by RT‐qPCR and digital droplet PCR, respectively. MACC1 and S100A4 transcripts were significantly elevated in serum of ovarian cancer patients, compared to healthy controls (P = 0.024; P < 0.001). At primary diagnosis, high levels of MACC1 or S100A4 correlated with advanced FIGO stage (P = 0.042; P = 0.008), predicted suboptimal debulking surgery and indicated shorter progression‐free survival (PFS; P = 0.003; P = 0.001) and overall survival (OS; P = 0.001; P = 0.002). This is the first study in ovarian cancer to propose circulating MACC1 and S100A4 transcripts as potential liquid biopsy markers. We analyzed the clinical relevance of circulating MACC1 and S100A4 transcripts in ovarian cancer patients. We report that high serum levels of both transcripts at primary diagnosis (but not in the course of surgery and chemotherapy) are associated with advanced disease and indicate poor survival. Our results suggest blood‐based MACC1 and S100A4 transcripts as innovative liquid biopsy markers for ovarian cancer.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Biopsy
/ Cancer
/ Cell-Free Nucleic Acids - blood
/ Female
/ Humans
/ Kinases
/ MACC1
/ Ovarian Neoplasms - mortality
/ Ovarian Neoplasms - pathology
/ Patients
/ Proteins
/ Real-Time Polymerase Chain Reaction
/ Reverse Transcriptase Polymerase Chain Reaction
/ S100 Calcium-Binding Protein A4
/ S100A4
/ Surgery
/ Survival
/ Tumors
